Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has completed the registration process to begin selling its C-Scrub Antimicrobial Wash in Germany, entering a market valued at $752.76 million in 2022. The company plans to target hospitals, wholesalers, and consumers through various channels, including online platforms like Amazon. Germany's antimicrobial market is projected to reach $1.05 billion by 2030, growing at a CAGR of 4.20%. CEO Greg Siokas expressed excitement about entering this key market and aims to capture a significant market share through both B2C and B2B strategies.

Positive

• Completed registration process to sell C-Scrub Antimicrobial Wash in Germany
• Entering a market valued at $752.76 million in 2022
• German antimicrobial market expected to reach $1.05 billion by 2030
• Diversified sales strategy targeting hospitals, wholesalers, and consumers

Negative

• None.

Insights

Market Research Analyst

The entry of Cosmos Health's C-Scrub into the German antimicrobial market is a strategic move with significant potential. With the market valued at $752.76 million in 2022 and projected to reach $1.05 billion by 2030, growing at a CAGR of 4.20%, there's ample room for new players. However, it's important to note that Cosmos Health is entering a mature market with established competitors.

The company's multi-channel approach, targeting hospitals, wholesalers and direct-to-consumer sales via Amazon, shows a comprehensive strategy. This diversification could help mitigate risks and accelerate market penetration. Yet, success will largely depend on C-Scrub's differentiation and pricing strategy in a crowded market.

Financial Analyst

While the completion of the registration process is a positive step for Cosmos Health, investors should temper their expectations. The company hasn't provided specific revenue projections or market share targets for C-Scrub in Germany. Without these figures, it's challenging to quantify the potential impact on Cosmos Health's financials.

Moreover, as a smaller player entering a large market, Cosmos Health may face significant marketing and distribution costs to establish its presence. These expenses could impact profitability in the short term. Investors should watch for future updates on sales traction, market share gains and any revisions to the company's financial guidance to better assess the long-term value of this market entry.

CHICAGO, IL / ACCESSWIRE / August 8, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has completed the registration process to commence sales in Germany of its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% Biocide ("C-Scrub").

The Company anticipates shipping orders to various entities in Germany as part of its comprehensive sales strategy, targeting a diverse range of customers, including hospitals and wholesalers, while also directly reaching consumers through its online stores on platforms like Amazon.

According to Markets & Data, Germany's antimicrobial market was valued at $752.76 million in 2022 and is expected to reach $1.05 billion by 2030, representing a CAGR of 4.20%.

Greg Siokas, CEO of Cosmos Health, stated: "We are excited to bring C-Scrub to the German market, a key market for us, and we look forward to expanding our presence there with both B2C and B2B strategies to capture a sizable market share."

About C-Scrub

C-Scrub, formulated with 4% chlorhexidine gluconate, provides up to 6 hours of powerful antimicrobial protection, even in the presence of biological fluids. Ideal for routine hand disinfection, it effectively targets bacteria, viruses, and fungi without fostering resistance. Gentle on the skin and iodine-free, it's an excellent choice for healthcare environments, including hospitals, clinics, and surgical suites.

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the Company's ability to regain compliance with Nasdaq listing requirements, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.

View the original press release on accesswire.com

FAQ

What product has Cosmos Health (COSM) registered for sale in Germany?

Cosmos Health has registered C-Scrub Wash Chlorhexidine 4% Biocide, an antimicrobial wash, for sale in Germany.

What is the current value of the German antimicrobial market that COSM is entering?

The German antimicrobial market was valued at $752.76 million in 2022.

What is the projected growth of the German antimicrobial market by 2030?

The German antimicrobial market is expected to reach $1.05 billion by 2030, with a CAGR of 4.20%.

How does Cosmos Health (COSM) plan to distribute C-Scrub in Germany?

COSM plans to distribute C-Scrub to hospitals and wholesalers, as well as directly to consumers through online platforms like Amazon.